IMFINZI(R) (durvalumab) Approved in the US in First and Only Immunotherapy Combination for Patients With BCG-naive, High-risk Non-muscle-invasive Bladder Cancer
May 29, 2026
May 29, 2026
WILMINGTON, Delaware, May 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
IMFINZI(R) (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naive, high-risk non-muscle-invasive bladder cancer
Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added t- BCG vs. BCG al . . .
* * *
IMFINZI(R) (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naive, high-risk non-muscle-invasive bladder cancer
Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added t- BCG vs. BCG al . . .